Further investigations, such as combining Lm-LLO-ISG15 with other forms of immunotherapy and/or approved therapies, might enhance the overall anti-tumor efficacy of Lm-LLO-ISG15 and provide further support for the clinical translational promise of this therapy. This evidence concerns the gene ISG15 and neoplasm.